res_code stringlengths 6 13 | treatment_phase stringclasses 432
values | authority_method stringclasses 3
values | treatment_of_code float64 4.08k 16.5k ⌀ | restriction_number float64 4.08k 16.5k ⌀ | li_html_text stringlengths 82 10.6k ⌀ | schedule_html_text stringlengths 41 12.3k | note_indicator stringclasses 2
values | caution_indicator stringclasses 2
values | complex_authority_rqrd_ind stringclasses 2
values | assessment_type_code stringclasses 2
values | criteria_relationship stringclasses 1
value | variation_rule_applied stringclasses 2
values | first_listing_date stringdate 1991-08-01 00:00:00 2025-05-01 00:00:00 | schedule_code int64 3.67k 3.67k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
11242_11261_R | Initial treatment - dose titration | AUTHORITY_REQUIRED | 11,261 | 11,242 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Pulmonary arterial hypertension (PAH)</p><br/><p>Initial treatment - dose titration</p><br/><p>Patient must have failed to achieve/maintain a WHO Functional Class II status with PAH agents (other than this agent) given as dual therapy; AND</p> <p>P... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Pulmonary arterial hypertension (PAH)</p><br/><p>Initial treatment - dose titration</p><br/><p>Patient must have failed to achieve/maintain a WHO Functional Class II status with PAH agents (other than this agent) given as dual therapy; AND</p> <p>P... | N | N | N | IMMEDIATE | ALL | N | 2021-02-01 | 3,671 |
11248_9073_R | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | AUTHORITY_REQUIRED | 9,073 | 11,248 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p><br/><p>Patient must have received prior PBS-subsidised treatment with a biolog... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p><br/><p>Patient must have received prior PBS-subsidised treatment with a biolog... | N | N | Y | FULL | ALL | N | 2021-02-01 | 3,671 |
11250_4368_R | Initial treatment for up to 3 months | AUTHORITY_REQUIRED | 4,368 | 11,250 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Eosinophilic oesophagitis</p><br/><p>Initial treatment for up to 3 months</p><br/><p>Must be treated by a clinical immunologist, suitably qualified allergist or gastroenterologist; AND</p> <p>Patient must require an amino acid based formula as a co... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Eosinophilic oesophagitis</p><br/><p>Initial treatment for up to 3 months</p><br/><p>Must be treated by a clinical immunologist, suitably qualified allergist or gastroenterologist; AND</p> <p>Patient must require an amino acid based formula as a co... | N | N | N | IMMEDIATE | ALL | N | 2021-02-01 | 3,671 |
11268_9155_R | Initial treatment - Initial 1 (new patient) | AUTHORITY_REQUIRED | 9,155 | 11,268 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>Initial treatment - Initial 1 (new patient)</p><br/><p>Must be treated by a rheumatologist; or</p> <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p> ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>Initial treatment - Initial 1 (new patient)</p><br/><p>Must be treated by a rheumatologist; or</p> <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p> ... | N | N | Y | FULL | ALL | N | 2021-02-01 | 3,671 |
11271_8892_R | Continuing treatment, Face, hand, foot | AUTHORITY_REQUIRED | 8,892 | 11,271 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Continuing treatment, Face, hand, foot</p><br/><p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p> <p>Patient mus... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Continuing treatment, Face, hand, foot</p><br/><p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p> <p>Patient mus... | N | N | Y | FULL | ALL | N | 2021-02-01 | 3,671 |
11272_4599_R | null | AUTHORITY_REQUIRED | 4,599 | 11,272 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Homocystinuria</p><br/><p>The treatment must be as adjunctive therapy to current standard care; AND</p> <p>The condition must be treated by or in consultation with a metabolic physician.</p> <p align="justify">The name of the specialist must be inc... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Homocystinuria</p><br/><p>The treatment must be as adjunctive therapy to current standard care; AND</p> <p>The condition must be treated by or in consultation with a metabolic physician.</p> <p align="justify">The name of the specialist must be inc... | N | N | N | IMMEDIATE | ALL | N | 2021-02-01 | 3,671 |
11293_6395_R | null | AUTHORITY_REQUIRED | 6,395 | 11,293 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Onychomycosis</p><br/><p>The condition must be proximal or extensive (greater than 80% nail involvement); AND</p> <p>Patient must have failed to respond to topical treatment; AND</p> <p>The condition must be due to dermatophyte infection proven by ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Onychomycosis</p><br/><p>The condition must be proximal or extensive (greater than 80% nail involvement); AND</p> <p>Patient must have failed to respond to topical treatment; AND</p> <p>The condition must be due to dermatophyte infection proven by ... | N | N | N | IMMEDIATE | ALL | N | 2021-02-01 | 3,671 |
11297_5341_R | Initial treatment | AUTHORITY_REQUIRED | 5,341 | 11,297 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Amyotrophic lateral sclerosis</p><br/><p>Initial treatment</p><br/><p>The condition must be diagnosed by a neurologist; AND</p> <p>Patient must not have had the disease for more than 5 years; AND</p> <p>Patient must have at least 60 percent of pred... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Amyotrophic lateral sclerosis</p><br/><p>Initial treatment</p><br/><p>The condition must be diagnosed by a neurologist; AND</p> <p>Patient must not have had the disease for more than 5 years; AND</p> <p>Patient must have at least 60 percent of pred... | N | N | N | IMMEDIATE | ALL | N | 2021-02-01 | 3,671 |
11310_11310_R | One of: (1) establishment of symptom control, (2) maintenance treatment, (3) re-establishment of symptom control | AUTHORITY_REQUIRED | 11,310 | 11,310 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Complex gastro-oesophageal reflux disease (GORD)</p><br/><p>One of: (1) establishment of symptom control, (2) maintenance treatment, (3) re-establishment of symptom control</p><br/><p>Must be treated by a gastroenterologist; or</p> <p>Must be treat... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Complex gastro-oesophageal reflux disease (GORD)</p><br/><p>One of: (1) establishment of symptom control, (2) maintenance treatment, (3) re-establishment of symptom control</p><br/><p>Must be treated by a gastroenterologist; or</p> <p>Must be treat... | N | N | N | IMMEDIATE | ALL | N | 2021-03-01 | 3,671 |
11334_8842_R | First continuing treatment, Face, hand, foot | AUTHORITY_REQUIRED | 8,842 | 11,334 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>First continuing treatment, Face, hand, foot</p><br/><p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p> <p>Patie... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>First continuing treatment, Face, hand, foot</p><br/><p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p> <p>Patie... | N | N | Y | FULL | ALL | N | 2021-03-01 | 3,671 |
11335_9162_R | First continuing treatment, Whole body | AUTHORITY_REQUIRED | 9,162 | 11,335 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>First continuing treatment, Whole body</p><br/><p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p> <p>Patient mus... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>First continuing treatment, Whole body</p><br/><p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p> <p>Patient mus... | N | N | Y | FULL | ALL | N | 2021-03-01 | 3,671 |
11337_9123_R | First continuing treatment | AUTHORITY_REQUIRED | 9,123 | 11,337 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>First continuing treatment</p><br/><p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p> <p>Patient must have demonstrat... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>First continuing treatment</p><br/><p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p> <p>Patient must have demonstrat... | N | N | Y | FULL | ALL | N | 2021-03-01 | 3,671 |
11347_8987_R | Continuing treatment, Face, hand, foot | AUTHORITY_REQUIRED | 8,987 | 11,347 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Continuing treatment, Face, hand, foot</p><br/><p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p> <p>Patient mus... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Continuing treatment, Face, hand, foot</p><br/><p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p> <p>Patient mus... | N | N | Y | FULL | ALL | N | 2021-03-01 | 3,671 |
11360_11360_R | null | STREAMLINED | 11,360 | 11,360 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Asthma</p><br/><p>Patient must have previously had frequent episodes of asthma while receiving treatment with oral corticosteroids or optimal doses of inhaled corticosteroids; AND</p> <p>Patient must be aged 12 years or over.</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Asthma</p><br/><p>Patient must have previously had frequent episodes of asthma while receiving treatment with oral corticosteroids or optimal doses of inhaled corticosteroids; AND</p> <p>Patient must be aged 12 years or over.</p> <p align="justify"... | N | N | N | IMMEDIATE | ALL | N | 2021-03-01 | 3,671 |
11368_8891_R | Continuing treatment, Whole body | AUTHORITY_REQUIRED | 8,891 | 11,368 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Continuing treatment, Whole body</p><br/><p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p> <p>Patient must have... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Continuing treatment, Whole body</p><br/><p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p> <p>Patient must have... | N | N | Y | FULL | ALL | N | 2021-03-01 | 3,671 |
11370_11370_R | One of: (1) establishment of symptom control, (2) maintenance treatment, (3) re-establishment of symptom control | AUTHORITY_REQUIRED | 11,370 | 11,370 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Complex gastro-oesophageal reflux disease (GORD)</p><br/><p>One of: (1) establishment of symptom control, (2) maintenance treatment, (3) re-establishment of symptom control</p><br/><p>Must be treated by a gastroenterologist; or</p> <p>Must be treat... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Complex gastro-oesophageal reflux disease (GORD)</p><br/><p>One of: (1) establishment of symptom control, (2) maintenance treatment, (3) re-establishment of symptom control</p><br/><p>Must be treated by a gastroenterologist; or</p> <p>Must be treat... | N | N | N | IMMEDIATE | ALL | N | 2021-03-01 | 3,671 |
11374_11374_R | Continuing or resuming treatment of the whole body | AUTHORITY_REQUIRED | 11,374 | 11,374 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic severe atopic dermatitis</p><br/><p>Continuing or resuming treatment of the whole body</p><br/><p>Patient must have received PBS-subsidised treatment with this biological medicine for the treatment of chronic severe atopic dermatitis affect... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic severe atopic dermatitis</p><br/><p>Continuing or resuming treatment of the whole body</p><br/><p>Patient must have received PBS-subsidised treatment with this biological medicine for the treatment of chronic severe atopic dermatitis affect... | N | N | N | IMMEDIATE | ALL | N | 2021-03-01 | 3,671 |
11377_11377_R | Continuing or resuming treatment of the face and/or hands | AUTHORITY_REQUIRED | 11,377 | 11,377 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic severe atopic dermatitis</p><br/><p>Continuing or resuming treatment of the face and/or hands</p><br/><p>Patient must have received PBS-subsidised treatment with this biological medicine for the treatment of chronic severe atopic dermatitis... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic severe atopic dermatitis</p><br/><p>Continuing or resuming treatment of the face and/or hands</p><br/><p>Patient must have received PBS-subsidised treatment with this biological medicine for the treatment of chronic severe atopic dermatitis... | N | N | N | IMMEDIATE | ALL | N | 2021-03-01 | 3,671 |
11429_N | null | null | null | null | null | <p/><p align="justify">A LAMA includes tiotropium, glycopyrronium, aclidinium or umeclidinium.</p><p/> | Y | N | N | null | null | N | 2014-11-01 | 3,671 |
11446_11445_R | null | STREAMLINED | 11,445 | 11,446 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Parkinson disease</p><br/><p>Patient must have experienced severely disabling motor fluctuations which have not responded to other therapy; AND</p> <p>The treatment must be commenced in a specialist unit in a hospital setting.</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Parkinson disease</p><br/><p>Patient must have experienced severely disabling motor fluctuations which have not responded to other therapy; AND</p> <p>The treatment must be commenced in a specialist unit in a hospital setting.</p> | N | N | N | IMMEDIATE | ALL | N | 2021-04-01 | 3,671 |
11449_11477_R | Continuing treatment as second-line drug therapy | STREAMLINED | 11,477 | 11,449 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Locally advanced or metastatic non-small cell lung cancer</p><br/><p>Continuing treatment as second-line drug therapy</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND</p> <p>The treatm... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Locally advanced or metastatic non-small cell lung cancer</p><br/><p>Continuing treatment as second-line drug therapy</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND</p> <p>The treatm... | N | N | N | IMMEDIATE | ALL | N | 2021-04-01 | 3,671 |
11451_11391_R | Continuing combination treatment (with nivolumab) of first-line drug therapy | STREAMLINED | 11,391 | 11,451 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Stage IV (metastatic) non-small cell lung cancer (NSCLC)</p><br/><p>Continuing combination treatment (with nivolumab) of first-line drug therapy</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condi... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Stage IV (metastatic) non-small cell lung cancer (NSCLC)</p><br/><p>Continuing combination treatment (with nivolumab) of first-line drug therapy</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condi... | N | N | N | IMMEDIATE | ALL | N | 2021-04-01 | 3,671 |
11461_11385_R | null | STREAMLINED | 11,385 | 11,461 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Parkinson disease</p><br/><p>Patient must have experienced severely disabling motor fluctuations which have not responded to other therapy; AND</p> <p>The treatment must be commenced in a specialist unit in a hospital setting.</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Parkinson disease</p><br/><p>Patient must have experienced severely disabling motor fluctuations which have not responded to other therapy; AND</p> <p>The treatment must be commenced in a specialist unit in a hospital setting.</p> | N | N | N | IMMEDIATE | ALL | N | 2021-04-01 | 3,671 |
11467_11478_R | Initial combination treatment (with nivolumab) as first-line drug therapy | STREAMLINED | 11,478 | 11,467 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Stage IV (metastatic) non-small cell lung cancer (NSCLC)</p><br/><p>Initial combination treatment (with nivolumab) as first-line drug therapy</p><br/><p>The condition must be squamous type non-small cell lung cancer (NSCLC); AND</p> <p>Patient must... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Stage IV (metastatic) non-small cell lung cancer (NSCLC)</p><br/><p>Initial combination treatment (with nivolumab) as first-line drug therapy</p><br/><p>The condition must be squamous type non-small cell lung cancer (NSCLC); AND</p> <p>Patient must... | N | N | N | IMMEDIATE | ALL | N | 2021-04-01 | 3,671 |
11468_11468_R | Continuing combination treatment (with ipilimumab) of first-line drug therapy | STREAMLINED | 11,468 | 11,468 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Stage IV (metastatic) non-small cell lung cancer (NSCLC)</p><br/><p>Continuing combination treatment (with ipilimumab) of first-line drug therapy</p><br/><p>The condition must be squamous type non-small cell lung cancer (NSCLC); AND</p> <p>Patient ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Stage IV (metastatic) non-small cell lung cancer (NSCLC)</p><br/><p>Continuing combination treatment (with ipilimumab) of first-line drug therapy</p><br/><p>The condition must be squamous type non-small cell lung cancer (NSCLC); AND</p> <p>Patient ... | N | N | N | IMMEDIATE | ALL | N | 2021-04-01 | 3,671 |
11468_N | null | null | null | null | null | <p align="justify">Not indicated for the treatment of intractable childhood epilepsy or cerebrospinal fluid glucose transporter defect requiring a ketogenic diet. </p> | Y | N | N | null | null | N | 2014-11-01 | 3,671 |
11473_11473_R | null | STREAMLINED | 11,473 | 11,473 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Locally advanced or metastatic breast cancer</p><br/><p>The condition must be hormone receptor positive; AND</p> <p>The condition must be human epidermal growth factor receptor 2 (HER2) negative; AND</p> <p>The condition must be inoperable; AND</p>... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Locally advanced or metastatic breast cancer</p><br/><p>The condition must be hormone receptor positive; AND</p> <p>The condition must be human epidermal growth factor receptor 2 (HER2) negative; AND</p> <p>The condition must be inoperable; AND</p>... | N | N | N | IMMEDIATE | ALL | N | 2021-04-01 | 3,671 |
11482_11482_R | null | RESTRICTED | 11,482 | 11,482 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Pyridoxine dependent epilepsy</p><br/><p>Patient must be managed on a low lysine diet for pyridoxine dependent epilepsy; AND</p> <p>The condition must be treated by or in consultation with a metabolic physician.</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Pyridoxine dependent epilepsy</p><br/><p>Patient must be managed on a low lysine diet for pyridoxine dependent epilepsy; AND</p> <p>The condition must be treated by or in consultation with a metabolic physician.</p> | N | N | N | IMMEDIATE | ALL | N | 2021-04-01 | 3,671 |
11494_10431_R | Continuing treatment | AUTHORITY_REQUIRED | 10,431 | 11,494 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Non-radiographic axial spondyloarthritis</p><br/><p>Continuing treatment</p><br/><p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p> <p>Patient must have de... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Non-radiographic axial spondyloarthritis</p><br/><p>Continuing treatment</p><br/><p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p> <p>Patient must have de... | N | N | Y | IMMEDIATE | ALL | N | 2021-04-01 | 3,671 |
11519_N | null | null | null | null | null | <p align="justify">For patients with graft versus host disease, acute myeloid leukaemia or myelodysplastic syndrome, applications for an increased maximum quantity to allow for up to 1 month's treatment and repeats sufficient for up to 6 months' treatment may be authorised. </p> | Y | N | N | null | null | N | 2014-12-01 | 3,671 |
11520_N | null | null | null | null | null | <p align="justify">For patients undergoing allogeneic haematopoietic stem cell transplant, applications for an increased maximum quantity to allow for up to 1 month's treatment and repeats sufficient for up to 2 months' treatment may be authorised.</p> | Y | N | N | null | null | N | 2014-12-01 | 3,671 |
11522_11604_R | Subsequent continuing treatment | STREAMLINED | 11,604 | 11,522 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe active juvenile idiopathic arthritis</p><br/><p>Subsequent continuing treatment</p><br/><p>Must be treated by a rheumatologist; or</p> <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AN... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe active juvenile idiopathic arthritis</p><br/><p>Subsequent continuing treatment</p><br/><p>Must be treated by a rheumatologist; or</p> <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AN... | N | N | N | IMMEDIATE | ALL | N | 2021-04-01 | 3,671 |
11527_11631_R | Subsequent continuing treatment | STREAMLINED | 11,631 | 11,527 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>Subsequent continuing treatment</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; or</p>... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>Subsequent continuing treatment</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; or</p>... | N | N | N | IMMEDIATE | ALL | N | 2021-04-01 | 3,671 |
11528_11529_R | Subsequent continuing treatment | STREAMLINED | 11,529 | 11,528 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe hidradenitis suppurativa</p><br/><p>Subsequent continuing treatment</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe hidradenitis suppurativa</p><br/><p>Subsequent continuing treatment</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND... | N | N | N | IMMEDIATE | ALL | N | 2021-04-01 | 3,671 |
11532_N | null | null | null | null | null | <p/><p align="justify">A patient may only qualify for PBS-subsidised treatment under this restriction once in a lifetime.</p><p/> | Y | N | N | null | null | N | 2014-12-01 | 3,671 |
11535_11635_R | Subsequent continuing treatment, Whole body | STREAMLINED | 11,635 | 11,535 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Subsequent continuing treatment, Whole body</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Subsequent continuing treatment, Whole body</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND... | N | N | N | IMMEDIATE | ALL | N | 2021-04-01 | 3,671 |
11580_11523_R | Subsequent continuing treatment | STREAMLINED | 11,523 | 11,580 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>Subsequent continuing treatment</p><br/><p>Must be treated by a rheumatologist; or</p> <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p> <p>Patient m... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>Subsequent continuing treatment</p><br/><p>Must be treated by a rheumatologist; or</p> <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p> <p>Patient m... | N | N | N | IMMEDIATE | ALL | N | 2021-04-01 | 3,671 |
11582_11579_R | Subsequent continuing treatment | STREAMLINED | 11,579 | 11,582 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe ulcerative colitis</p><br/><p>Subsequent continuing treatment</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology (... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe ulcerative colitis</p><br/><p>Subsequent continuing treatment</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology (... | N | N | N | IMMEDIATE | ALL | N | 2021-04-01 | 3,671 |
11595_N | null | null | null | null | null | <p/><p align="justify">Application for an increased maximum quantity to allow for up to 1 month's treatment and repeats sufficient for up to 6 months' treatment may be authorised.</p><p/> | Y | N | N | null | null | N | 2014-12-01 | 3,671 |
11630_11606_R | Subsequent continuing treatment, Face, hand, foot | STREAMLINED | 11,606 | 11,630 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Subsequent continuing treatment, Face, hand, foot</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restrictio... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Subsequent continuing treatment, Face, hand, foot</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restrictio... | N | N | N | IMMEDIATE | ALL | N | 2021-04-01 | 3,671 |
11637_11524_R | Subsequent continuing treatment | STREAMLINED | 11,524 | 11,637 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Complex refractory Fistulising Crohn disease</p><br/><p>Subsequent continuing treatment</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenter... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Complex refractory Fistulising Crohn disease</p><br/><p>Subsequent continuing treatment</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenter... | N | N | N | IMMEDIATE | ALL | N | 2021-04-01 | 3,671 |
11643_11642_R | null | STREAMLINED | 11,642 | 11,643 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe myoclonic epilepsy in infancy (Dravet syndrome)</p><br/><p>Patient must have (as an initiating patient)/have had (as a continuing patient), generalised tonic-clonic seizures or generalised clonic seizures that are not adequately controlled w... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe myoclonic epilepsy in infancy (Dravet syndrome)</p><br/><p>Patient must have (as an initiating patient)/have had (as a continuing patient), generalised tonic-clonic seizures or generalised clonic seizures that are not adequately controlled w... | N | N | N | IMMEDIATE | ALL | N | 2021-05-01 | 3,671 |
11658_11644_R | null | RESTRICTED | 11,644 | 11,658 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Ketogenic diet</p><br/><p>Patient must have intractable seizures requiring treatment with a ketogenic diet; or</p> <p>Patient must have a glucose transport protein defect; or</p> <p>Patient must have pyruvate dehydrogenase deficiency; AND</p> <p>Pa... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Ketogenic diet</p><br/><p>Patient must have intractable seizures requiring treatment with a ketogenic diet; or</p> <p>Patient must have a glucose transport protein defect; or</p> <p>Patient must have pyruvate dehydrogenase deficiency; AND</p> <p>Pa... | N | N | N | IMMEDIATE | ALL | N | 2021-06-01 | 3,671 |
11673_11673_R | null | STREAMLINED | 11,673 | 11,673 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Prevention of preterm birth</p><br/><p>Patient must have a singleton pregnancy; AND</p> <p>Patient must have at least one of: (i) short cervix (mid-trimester sonographic cervix no greater than 25 mm), (ii) a history of spontaneous preterm birth; AN... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Prevention of preterm birth</p><br/><p>Patient must have a singleton pregnancy; AND</p> <p>Patient must have at least one of: (i) short cervix (mid-trimester sonographic cervix no greater than 25 mm), (ii) a history of spontaneous preterm birth; AN... | N | N | N | IMMEDIATE | ALL | N | 2021-06-01 | 3,671 |
11681_11681_R | null | AUTHORITY_REQUIRED | 11,681 | 11,681 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe myoclonic epilepsy in infancy (Dravet syndrome)</p><br/><p>Patient must have (as an initiating patient)/have had (as a continuing patient), generalised tonic-clonic seizures or generalised clonic seizures that are not adequately controlled w... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe myoclonic epilepsy in infancy (Dravet syndrome)</p><br/><p>Patient must have (as an initiating patient)/have had (as a continuing patient), generalised tonic-clonic seizures or generalised clonic seizures that are not adequately controlled w... | N | N | N | IMMEDIATE | ALL | N | 2021-05-01 | 3,671 |
11682_11680_R | null | STREAMLINED | 11,680 | 11,682 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic heart failure</p><br/><p>Patient must be symptomatic with NYHA classes II, III or IV; AND</p> <p>Patient must have a documented left ventricular ejection fraction (LVEF) of less than or equal to 40%; AND</p> <p>Patient must receive concomit... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic heart failure</p><br/><p>Patient must be symptomatic with NYHA classes II, III or IV; AND</p> <p>Patient must have a documented left ventricular ejection fraction (LVEF) of less than or equal to 40%; AND</p> <p>Patient must receive concomit... | N | N | N | IMMEDIATE | ALL | N | 2021-06-01 | 3,671 |
11683_11683_R | null | RESTRICTED | 11,683 | 11,683 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>For use in patients receiving palliative care</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>For use in patients receiving palliative care</p> | N | N | N | IMMEDIATE | ALL | N | 2021-06-01 | 3,671 |
11696_11696_R | null | AUTHORITY_REQUIRED | 11,696 | 11,696 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe disabling pain</p><br/><p>Patient must not be opioid naive; AND</p> <p>Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid and other opioid analgesics; or</p> <p>Patient must be unable to... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe disabling pain</p><br/><p>Patient must not be opioid naive; AND</p> <p>Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid and other opioid analgesics; or</p> <p>Patient must be unable to... | N | N | N | IMMEDIATE | ALL | Y | 2021-06-01 | 3,671 |
11697_11697_R | null | STREAMLINED | 11,697 | 11,697 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe pain</p><br/><p>Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid and other opioid analgesics; or</p> <p>Patient must be unable to use non-opioid and other opioid analgesics due to cont... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe pain</p><br/><p>Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid and other opioid analgesics; or</p> <p>Patient must be unable to use non-opioid and other opioid analgesics due to cont... | N | N | N | IMMEDIATE | ALL | Y | 2021-06-01 | 3,671 |
11698_6986_R | Continuing | STREAMLINED | 6,986 | 11,698 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>HIV infection</p><br/><p>Continuing</p><br/><p>Patient must have previously received PBS-subsidised therapy for HIV infection; AND</p> <p>The treatment must be in combination with other antiretroviral agents.</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>HIV infection</p><br/><p>Continuing</p><br/><p>Patient must have previously received PBS-subsidised therapy for HIV infection; AND</p> <p>The treatment must be in combination with other antiretroviral agents.</p> | N | N | N | IMMEDIATE | ALL | N | 2021-06-01 | 3,671 |
11702_11763_R | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | AUTHORITY_REQUIRED | 11,763 | 11,702 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consu... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consu... | N | N | N | FULL | ALL | N | 2021-06-01 | 3,671 |
11703_11759_R | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | AUTHORITY_REQUIRED | 11,759 | 11,703 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated ... | N | N | Y | FULL | ALL | N | 2021-06-01 | 3,671 |
11705_11709_R | Balance of supply | AUTHORITY_REQUIRED | 11,709 | 11,705 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>Balance of supply</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; or</p> <p>Must be tr... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>Balance of supply</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; or</p> <p>Must be tr... | N | N | Y | IMMEDIATE | ALL | N | 2021-06-01 | 3,671 |
11710_11711_R | Subsequent continuing treatment | AUTHORITY_REQUIRED | 11,711 | 11,710 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>Subsequent continuing treatment</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; or</p>... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>Subsequent continuing treatment</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; or</p>... | N | N | N | FULL | ALL | N | 2021-06-01 | 3,671 |
11712_11761_R | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | AUTHORITY_REQUIRED | 11,761 | 11,712 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p><br/><p>Patient must have a documented history of severe Crohn disease; AND</p> <p>Pa... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p><br/><p>Patient must have a documented history of severe Crohn disease; AND</p> <p>Pa... | N | N | N | FULL | ALL | N | 2021-06-01 | 3,671 |
11714_11717_R | Subsequent continuing treatment of Crohn disease in a paediatric patient assessed by PCDAI | AUTHORITY_REQUIRED | 11,717 | 11,714 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>Subsequent continuing treatment of Crohn disease in a paediatric patient assessed by PCDAI</p><br/><p>Patient must have a documented history of severe Crohn disease; AND</p> <p>Patient must have previously received P... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>Subsequent continuing treatment of Crohn disease in a paediatric patient assessed by PCDAI</p><br/><p>Patient must have a documented history of severe Crohn disease; AND</p> <p>Patient must have previously received P... | N | N | N | FULL | ALL | N | 2021-06-01 | 3,671 |
11745_11746_R | null | RESTRICTED | 11,746 | 11,745 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>For use in patients receiving palliative care</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>For use in patients receiving palliative care</p> | N | N | N | IMMEDIATE | ALL | N | 2021-06-01 | 3,671 |
11753_11753_R | null | AUTHORITY_REQUIRED | 11,753 | 11,753 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe disabling pain</p><br/><p>Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid or other opioid analgesics; or</p> <p>Patient must be unable to use non-opioid or other opioid analgesics due... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe disabling pain</p><br/><p>Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid or other opioid analgesics; or</p> <p>Patient must be unable to use non-opioid or other opioid analgesics due... | N | N | N | IMMEDIATE | ALL | Y | 2021-06-01 | 3,671 |
11754_6985_R | Initial | STREAMLINED | 6,985 | 11,754 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>HIV infection</p><br/><p>Initial</p><br/><p>Patient must be antiretroviral treatment naive; AND</p> <p>The treatment must be in combination with other antiretroviral agents.</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>HIV infection</p><br/><p>Initial</p><br/><p>Patient must be antiretroviral treatment naive; AND</p> <p>The treatment must be in combination with other antiretroviral agents.</p> | N | N | N | IMMEDIATE | ALL | N | 2021-06-01 | 3,671 |
11756_11815_R | Induction treatment | AUTHORITY_REQUIRED | 11,815 | 11,756 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Stage II bulky or Stage III/IV follicular lymphoma</p><br/><p>Induction treatment</p><br/><p>The condition must be CD20 positive; AND</p> <p>The condition must be previously untreated; AND</p> <p>The condition must be symptomatic; AND</p> <p>The tr... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Stage II bulky or Stage III/IV follicular lymphoma</p><br/><p>Induction treatment</p><br/><p>The condition must be CD20 positive; AND</p> <p>The condition must be previously untreated; AND</p> <p>The condition must be symptomatic; AND</p> <p>The tr... | N | N | N | IMMEDIATE | ALL | N | 2021-06-01 | 3,671 |
11757_11785_R | Maintenance therapy | AUTHORITY_REQUIRED | 11,785 | 11,757 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Follicular lymphoma</p><br/><p>Maintenance therapy</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug under the rituximab refractory initial restriction; AND</p> <p>The condition must be CD20 positive; AND</p> ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Follicular lymphoma</p><br/><p>Maintenance therapy</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug under the rituximab refractory initial restriction; AND</p> <p>The condition must be CD20 positive; AND</p> ... | N | N | N | IMMEDIATE | ALL | N | 2021-06-01 | 3,671 |
11764_11713_R | Balance of supply for paediatric patient | AUTHORITY_REQUIRED | 11,713 | 11,764 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>Balance of supply for paediatric patient</p><br/><p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>Balance of supply for paediatric patient</p><br/><p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</... | N | N | N | IMMEDIATE | ALL | N | 2021-06-01 | 3,671 |
11766_11767_R | First continuing treatment of Crohn disease in a paediatric patient assessed by PCDAI | AUTHORITY_REQUIRED | 11,767 | 11,766 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>First continuing treatment of Crohn disease in a paediatric patient assessed by PCDAI</p><br/><p>Patient must have a documented history of severe Crohn disease; AND</p> <p>Patient must have received this drug as thei... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>First continuing treatment of Crohn disease in a paediatric patient assessed by PCDAI</p><br/><p>Patient must have a documented history of severe Crohn disease; AND</p> <p>Patient must have received this drug as thei... | N | N | N | FULL | ALL | N | 2021-06-01 | 3,671 |
11786_11787_R | Maintenance therapy | AUTHORITY_REQUIRED | 11,787 | 11,786 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Stage II bulky or Stage III/IV follicular lymphoma</p><br/><p>Maintenance therapy</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug under the previously untreated initial restriction; AND</p> <p>The condition ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Stage II bulky or Stage III/IV follicular lymphoma</p><br/><p>Maintenance therapy</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug under the previously untreated initial restriction; AND</p> <p>The condition ... | N | N | N | IMMEDIATE | ALL | N | 2021-06-01 | 3,671 |
11788_11704_R | First continuing treatment | AUTHORITY_REQUIRED | 11,704 | 11,788 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>First continuing treatment</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; or</p> <p>M... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>First continuing treatment</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; or</p> <p>M... | N | N | N | FULL | ALL | N | 2021-06-01 | 3,671 |
11800_11699_R | Maintenance therapy - Continuing treatment | AUTHORITY_REQUIRED | 11,699 | 11,800 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Acute Myeloid Leukaemia</p><br/><p>Maintenance therapy - Continuing treatment</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the initial maintenance treatment restriction; AND</p> <... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Acute Myeloid Leukaemia</p><br/><p>Maintenance therapy - Continuing treatment</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the initial maintenance treatment restriction; AND</p> <... | N | N | N | IMMEDIATE | ALL | N | 2021-06-01 | 3,671 |
11802_11759_R | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | AUTHORITY_REQUIRED | 11,759 | 11,802 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated ... | N | N | N | FULL | ALL | N | 2021-06-01 | 3,671 |
11803_11762_R | Initial treatment - Initial 1 (new patient) | AUTHORITY_REQUIRED | 11,762 | 11,803 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>Initial treatment - Initial 1 (new patient)</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>Initial treatment - Initial 1 (new patient)</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code ... | N | N | N | FULL | ALL | N | 2021-06-01 | 3,671 |
11804_11718_R | Subsequent continuing treatment of Crohn disease in a paediatric patient assessed by PCDAI | STREAMLINED | 11,718 | 11,804 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>Subsequent continuing treatment of Crohn disease in a paediatric patient assessed by PCDAI</p><br/><p>Patient must have a documented history of severe Crohn disease; AND</p> <p>Patient must have previously received P... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe Crohn disease</p><br/><p>Subsequent continuing treatment of Crohn disease in a paediatric patient assessed by PCDAI</p><br/><p>Patient must have a documented history of severe Crohn disease; AND</p> <p>Patient must have previously received P... | N | N | N | IMMEDIATE | ALL | N | 2021-06-01 | 3,671 |
11809_11755_R | Re-induction treatment | AUTHORITY_REQUIRED | 11,755 | 11,809 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Follicular lymphoma</p><br/><p>Re-induction treatment</p><br/><p>Patient must not have previously received PBS-subsidised obinutuzumab; AND</p> <p>The condition must be CD20 positive; AND</p> <p>The condition must be refractory to treatment with ri... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Follicular lymphoma</p><br/><p>Re-induction treatment</p><br/><p>Patient must not have previously received PBS-subsidised obinutuzumab; AND</p> <p>The condition must be CD20 positive; AND</p> <p>The condition must be refractory to treatment with ri... | N | N | N | IMMEDIATE | ALL | N | 2021-06-01 | 3,671 |
11819_11784_R | null | STREAMLINED | 11,784 | 11,819 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic migraine</p><br/><p>Must be treated by a neurologist; AND</p> <p>Patient must have experienced an average of 15 or more headache days per month, with at least 8 days of migraine, over a period of at least 6 months, prior to commencement of ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p align="justify">Contraindications to treatment include known sensitivity to botulinum toxin.</p> <p>Chronic migraine</p><br/><p>Must be treated by a neurologist; AND</p> <p>Patient must have experienced an average of 15 or more headache days per mo... | N | N | N | IMMEDIATE | ALL | N | 2021-06-01 | 3,671 |
11829_11939_R | Continuing treatment beyond 3 months | STREAMLINED | 11,939 | 11,829 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Stage IV clear cell variant renal cell carcinoma (RCC)</p><br/><p>Continuing treatment beyond 3 months</p><br/><p>Patient must have received an initial authority prescription for this drug for this condition; AND</p> <p>Patient must have stable or ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Stage IV clear cell variant renal cell carcinoma (RCC)</p><br/><p>Continuing treatment beyond 3 months</p><br/><p>Patient must have received an initial authority prescription for this drug for this condition; AND</p> <p>Patient must have stable or ... | N | N | N | IMMEDIATE | ALL | N | 2021-07-01 | 3,671 |
11830_11915_R | Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 5 years) | AUTHORITY_REQUIRED | 11,915 | 11,830 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe ulcerative colitis</p><br/><p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 5 years)</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe ulcerative colitis</p><br/><p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 5 years)</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <... | N | N | Y | FULL | ALL | N | 2021-07-01 | 3,671 |
11831_11890_R | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | AUTHORITY_REQUIRED | 11,890 | 11,831 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p><br/><p>Must be treated by a rheumatologist; or</p> <p>Must be treated by a cli... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p><br/><p>Must be treated by a rheumatologist; or</p> <p>Must be treated by a cli... | N | N | Y | FULL | ALL | N | 2021-07-01 | 3,671 |
11832_11981_R | Initial treatment - Initial 1 (new patient) | AUTHORITY_REQUIRED | 11,981 | 11,832 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>Initial treatment - Initial 1 (new patient)</p><br/><p>Must be treated by a rheumatologist; or</p> <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p> ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>Initial treatment - Initial 1 (new patient)</p><br/><p>Must be treated by a rheumatologist; or</p> <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p> ... | N | N | Y | FULL | ALL | N | 2021-07-01 | 3,671 |
11833_11834_R | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | AUTHORITY_REQUIRED | 11,834 | 11,833 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p><br/><p>Must be treated by a rheumatologist; or</p> <p>Must be treated by a clinical immu... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p><br/><p>Must be treated by a rheumatologist; or</p> <p>Must be treated by a clinical immu... | N | N | Y | FULL | ALL | N | 2021-07-01 | 3,671 |
11835_11835_R | null | STREAMLINED | 11,835 | 11,835 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Prevention of preterm birth</p><br/><p>Patient must have a singleton pregnancy; AND</p> <p>Patient must have at least one of: (i) short cervix (mid-trimester sonographic cervix no greater than 25 mm), (ii) a history of spontaneous preterm birth; AN... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Prevention of preterm birth</p><br/><p>Patient must have a singleton pregnancy; AND</p> <p>Patient must have at least one of: (i) short cervix (mid-trimester sonographic cervix no greater than 25 mm), (ii) a history of spontaneous preterm birth; AN... | N | N | N | IMMEDIATE | ALL | N | 2021-07-01 | 3,671 |
11837_11960_R | Existing pregnancy to birth | AUTHORITY_REQUIRED | 11,960 | 11,837 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Maternal hyperphenylalaninaemia (HPA) due to phenylketonuria (PKU)</p><br/><p>Existing pregnancy to birth</p><br/><p>Patient must be pregnant; AND</p> <p>Patient must have demonstrated an adequate response to treatment with this drug at least once ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Maternal hyperphenylalaninaemia (HPA) due to phenylketonuria (PKU)</p><br/><p>Existing pregnancy to birth</p><br/><p>Patient must be pregnant; AND</p> <p>Patient must have demonstrated an adequate response to treatment with this drug at least once ... | N | N | N | IMMEDIATE | ALL | N | 2021-07-01 | 3,671 |
11849_11966_R | Continuing treatment - balance of supply | AUTHORITY_REQUIRED | 11,966 | 11,849 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe ulcerative colitis</p><br/><p>Continuing treatment - balance of supply</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroent... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe ulcerative colitis</p><br/><p>Continuing treatment - balance of supply</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroent... | N | N | N | IMMEDIATE | ALL | N | 2021-07-01 | 3,671 |
11850_11853_R | Subsequent continuing treatment | AUTHORITY_REQUIRED | 11,853 | 11,850 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe ulcerative colitis</p><br/><p>Subsequent continuing treatment</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology (... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe ulcerative colitis</p><br/><p>Subsequent continuing treatment</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology (... | N | N | N | IMMEDIATE | ALL | N | 2021-07-01 | 3,671 |
11856_9715_R | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | AUTHORITY_REQUIRED | 9,715 | 11,856 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe ulcerative colitis</p><br/><p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biolo... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe ulcerative colitis</p><br/><p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biolo... | N | N | Y | IMMEDIATE | ALL | N | 2021-07-01 | 3,671 |
11859_9064_R | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | AUTHORITY_REQUIRED | 9,064 | 11,859 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medic... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medic... | N | N | Y | IMMEDIATE | ALL | N | 2021-07-01 | 3,671 |
11862_11867_R | First continuing treatment | AUTHORITY_REQUIRED | 11,867 | 11,862 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>First continuing treatment</p><br/><p>Must be treated by a rheumatologist; or</p> <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p> <p>Patient must h... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>First continuing treatment</p><br/><p>Must be treated by a rheumatologist; or</p> <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p> <p>Patient must h... | N | N | Y | FULL | ALL | N | 2021-07-01 | 3,671 |
11863_11865_R | Subsequent continuing treatment | AUTHORITY_REQUIRED | 11,865 | 11,863 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>Subsequent continuing treatment</p><br/><p>Must be treated by a rheumatologist; or</p> <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p> <p>Patient m... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>Subsequent continuing treatment</p><br/><p>Must be treated by a rheumatologist; or</p> <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p> <p>Patient m... | N | N | Y | FULL | ALL | N | 2021-07-01 | 3,671 |
11876_11974_R | Initial treatment | STREAMLINED | 11,974 | 11,876 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Stage IV clear cell variant renal cell carcinoma (RCC)</p><br/><p>Initial treatment</p><br/><p>The condition must be classified as favourable to intermediate risk according to the International Metastatic Renal Cell Carcinoma Database Consortium (I... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Stage IV clear cell variant renal cell carcinoma (RCC)</p><br/><p>Initial treatment</p><br/><p>The condition must be classified as favourable to intermediate risk according to the International Metastatic Renal Cell Carcinoma Database Consortium (I... | N | N | N | IMMEDIATE | ALL | N | 2021-07-01 | 3,671 |
11877_11937_R | Continuing treatment beyond 3 months | STREAMLINED | 11,937 | 11,877 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Stage IV clear cell variant renal cell carcinoma (RCC)</p><br/><p>Continuing treatment beyond 3 months</p><br/><p>Patient must have received an initial authority prescription for this drug for this condition; AND</p> <p>Patient must have stable or ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Stage IV clear cell variant renal cell carcinoma (RCC)</p><br/><p>Continuing treatment beyond 3 months</p><br/><p>Patient must have received an initial authority prescription for this drug for this condition; AND</p> <p>Patient must have stable or ... | N | N | N | IMMEDIATE | ALL | N | 2021-07-01 | 3,671 |
11881_11975_R | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | AUTHORITY_REQUIRED | 11,975 | 11,881 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe ulcerative colitis</p><br/><p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be t... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe ulcerative colitis</p><br/><p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be t... | N | N | Y | FULL | ALL | N | 2021-07-01 | 3,671 |
11885_11886_R | Continuing treatment - balance of supply | AUTHORITY_REQUIRED | 11,886 | 11,885 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>Continuing treatment - balance of supply</p><br/><p>Must be treated by a rheumatologist; or</p> <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p> <p>... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>Continuing treatment - balance of supply</p><br/><p>Must be treated by a rheumatologist; or</p> <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p> <p>... | N | N | Y | IMMEDIATE | ALL | N | 2021-07-01 | 3,671 |
11887_11919_R | Initial treatment - Initial 1 (new patient) | AUTHORITY_REQUIRED | 11,919 | 11,887 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>Initial treatment - Initial 1 (new patient)</p><br/><p>Must be treated by a rheumatologist; or</p> <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p> ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>Initial treatment - Initial 1 (new patient)</p><br/><p>Must be treated by a rheumatologist; or</p> <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p> ... | N | N | Y | FULL | ALL | N | 2021-07-01 | 3,671 |
11888_11979_R | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | AUTHORITY_REQUIRED | 11,979 | 11,888 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p><br/><p>Must be treated by a rheumatologist; or</p> <p>Must be treated by a clinical immu... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p><br/><p>Must be treated by a rheumatologist; or</p> <p>Must be treated by a clinical immu... | N | N | Y | FULL | ALL | N | 2021-07-01 | 3,671 |
11889_9172_R | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | AUTHORITY_REQUIRED | 9,172 | 11,889 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medic... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medic... | N | N | Y | IMMEDIATE | ALL | N | 2021-07-01 | 3,671 |
11907_8555_R | Induction treatment | STREAMLINED | 8,555 | 11,907 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Stage IV clear cell variant renal cell carcinoma (RCC)</p><br/><p>Induction treatment</p><br/><p>The condition must not have previously been treated; AND</p> <p>The condition must be classified as intermediate to poor risk according to the Internat... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p align="justify">Combination treatment with ipilimumab and nivolumab is associated with an increased incidence and severity of immune-related adverse reactions compared with monotherapy with these agents. Monitoring at least prior to each dose is re... | N | N | N | IMMEDIATE | ALL | N | 2021-07-01 | 3,671 |
11908_11930_R | null | STREAMLINED | 11,930 | 11,908 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Unresectable malignant mesothelioma</p><br/><p>Patient must have a WHO performance status of 0 or 1; AND</p> <p>The treatment must be in combination with PBS-subsidised nivolumab for this condition; AND</p> <p>Patient must not have developed diseas... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Unresectable malignant mesothelioma</p><br/><p>Patient must have a WHO performance status of 0 or 1; AND</p> <p>The treatment must be in combination with PBS-subsidised nivolumab for this condition; AND</p> <p>Patient must not have developed diseas... | N | N | N | IMMEDIATE | ALL | N | 2021-07-01 | 3,671 |
11914_11878_R | Initial treatment | STREAMLINED | 11,878 | 11,914 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Stage IV clear cell variant renal cell carcinoma (RCC)</p><br/><p>Initial treatment</p><br/><p>The condition must be classified as favourable to intermediate risk according to the International Metastatic Renal Cell Carcinoma Database Consortium (I... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Stage IV clear cell variant renal cell carcinoma (RCC)</p><br/><p>Initial treatment</p><br/><p>The condition must be classified as favourable to intermediate risk according to the International Metastatic Renal Cell Carcinoma Database Consortium (I... | N | N | N | IMMEDIATE | ALL | N | 2021-07-01 | 3,671 |
11920_9172_R | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | AUTHORITY_REQUIRED | 9,172 | 11,920 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medic... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medic... | N | N | Y | IMMEDIATE | ALL | N | 2021-07-01 | 3,671 |
11921_11959_R | Continuing treatment | AUTHORITY_REQUIRED | 11,959 | 11,921 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>Continuing treatment</p><br/><p>Must be treated by a rheumatologist; or</p> <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p> <p>Patient must have re... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>Continuing treatment</p><br/><p>Must be treated by a rheumatologist; or</p> <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p> <p>Patient must have re... | N | N | Y | FULL | ALL | N | 2021-07-01 | 3,671 |
11928_11903_R | First continuing treatment | AUTHORITY_REQUIRED | 11,903 | 11,928 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe ulcerative colitis</p><br/><p>First continuing treatment</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe ulcerative colitis</p><br/><p>First continuing treatment</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code ... | N | N | N | IMMEDIATE | ALL | N | 2021-07-01 | 3,671 |
11929_11906_R | Continuing treatment - balance of supply | AUTHORITY_REQUIRED | 11,906 | 11,929 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>Continuing treatment - balance of supply</p><br/><p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatm... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe psoriatic arthritis</p><br/><p>Continuing treatment - balance of supply</p><br/><p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatm... | N | N | Y | IMMEDIATE | ALL | N | 2021-07-01 | 3,671 |
11935_11826_R | Continuing treatment with subcutaneous form or switching from intravenous form to subcutaneous form | AUTHORITY_REQUIRED | 11,826 | 11,935 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe ulcerative colitis</p><br/><p>Continuing treatment with subcutaneous form or switching from intravenous form to subcutaneous form</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consul... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe ulcerative colitis</p><br/><p>Continuing treatment with subcutaneous form or switching from intravenous form to subcutaneous form</p><br/><p>Must be treated by a gastroenterologist (code 87); or</p> <p>Must be treated by a consul... | N | N | Y | IMMEDIATE | ALL | N | 2021-07-01 | 3,671 |
11938_11875_R | Continuing treatment beyond 3 months | STREAMLINED | 11,875 | 11,938 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Stage IV clear cell variant renal cell carcinoma (RCC)</p><br/><p>Continuing treatment beyond 3 months</p><br/><p>Patient must have received an initial authority prescription for this drug for this condition; AND</p> <p>Patient must have stable or ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Stage IV clear cell variant renal cell carcinoma (RCC)</p><br/><p>Continuing treatment beyond 3 months</p><br/><p>Patient must have received an initial authority prescription for this drug for this condition; AND</p> <p>Patient must have stable or ... | N | N | N | IMMEDIATE | ALL | N | 2021-07-01 | 3,671 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.